Whalesbook
Indian pharma experts are raising concerns over the government's proposal to set minimum import prices (MIP) for key pharmaceutical inputs like Penicillin-G, 6APA, and amoxicillin. This move, aimed at boosting domestic production and reducing reliance on China, could artificially inflate manufacturing costs for APIs and formulations. Industry leaders warn of severe impacts on micro, small, and medium enterprises (MSMEs), potentially leading to widespread closures and significant job losses, alongside a projected 40% rise in medicine prices in government tenders.